For the first time, a genetically modified plant patent is litigated in the United Kingdom's High Court.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Monsanto Technology LLC v. Cargill International SA and Cargill plc (2007) EWHC 2257 (Pat.).
Monsanto applied to amend the patent a few weeks before the trial to restrict its scope only to the commercial embodiment of the invention.
Monsanto used the term “Class II” to describe those enzymes that could be identified through homology testing with other EPSPS enzymes as being part of its invention.
This application was made via a “revalidation” route.
These two sequences corresponded to the CP4 and PG2982 EPSPS enzyme amino acid sequences, respectively.
See Novartis AG v. Ivax Pharmaceuticals UK Ltd. (2007) EWCA Civ. 971.
See also Kirin-Amgen v. Hoechst (2004) UKHL 46.
Infringement was therefore claimed under section 60(1)(c) of the UK Patents Act 1977 as amended.
See Pioneer v. Warner (1997) RPC 759.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors are employed by Taylor Wessing LLP, which acted for Cargill in defending Monsanto's claim for patent infringement.
Rights and permissions
About this article
Cite this article
Cohen, S., Morgan, G. Monsanto Technology LLC v. Cargill: a matter of construction. Nat Biotechnol 26, 289–291 (2008). https://doi.org/10.1038/nbt0308-289
Issue Date:
DOI: https://doi.org/10.1038/nbt0308-289
This article is cited by
-
A shadow falls over gene patents in the United States and Europe
Nature Biotechnology (2010)